Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13072367 | 0.74 | OPRM1 (0.34) | HCRTR1 | |
| SCHEMBL20170650 | 0.73 | HCRTR1 (0.44) | HCRTR1ADRA1AHTR1A | |
| SCHEMBL20170778 | 0.70 | HCRTR1 (0.33) | HCRTR1 | |
| SCHEMBL13972294 | 0.66 | HCRTR1 (0.41) | HCRTR1MRGPRX2HTR1A | |
| SCHEMBL18473438 | 0.66 | HCRTR1 (0.41) | HCRTR1MRGPRX2HTR1A | |
| SCHEMBL13972295 | 0.66 | HCRTR1 (0.41) | HCRTR1MRGPRX2HTR1A | |
| SCHEMBL20170731 | 0.64 | HCRTR1 (0.43) | HCRTR1HTR1A | |
| SCHEMBL20170703 | 0.64 | HCRTR1 (0.47) | HCRTR1MRGPRX2MAPTHTR1A | |
| SCHEMBL20170880 | 0.64 | HCRTR1 (0.45) | HCRTR1HTR1A | |
| SCHEMBL20170657 | 0.63 | MTNR1A (0.43) | HCRTR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453895-B1 | (+) - MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC (US) | 2018-05-23 | — | — | EP | disclosed |